Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is enrolling a 28-day Phase 1 clinical trial in combination with Pegasys(R) and Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.
Lexiva(R), Agenerase(R), Mepron(R) and Malarone(R) are registered trademarks of GlaxoSmithKline.
Alan Roemer, Vice President
Investor Relations & Corporate Communications
Office: (609) 613-4125
Pharmasset "Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995: Statements in this press release regarding
our business that are not historical facts are "forward-looking statements"
that involve risks and uncertainties, including without limitation the risk
that our collaboration with Roche will not continue or will not be
successful, the risk that the on-going or anticipated clinical trials for
any one or more of our product candidates will not be successful or will
not provide meaningful data and the risk that any one or more of our
product candidates will not be successfully developed and commercialized.
For a discussion of these risks and uncertainties, any of which could cause
our actual results to differ from those contained in the forward-looking
|SOURCE Pharmasset, Inc.|
Copyright©2007 PR Newswire.
All rights reserved